斯派格拉斯制药 SGP
$36.95 +$2.87 (+8.41%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $36.95 0.00%
开盘$34.50
昨收$34.08
当日区间$33.92 – $37.12
成交量109.4K
市值$1.24B
市盈率（TTM）–
股息率–
SGP 相关新闻
匹配 SpyGlass Pharma 或代码 SGP 的头条新闻，按最新排序。
- Dentsu Ventures SGP Fund invests in Facilo, a company supporting digital transformation in the real estate industry.
- Analysts Offer Insights on NA Companies: Ottobock SE & Co. KGaA (OtherOBCKF), SpyGlass Pharma (Nasdaq: SGP) and Figure Technology Solutions, Inc. Class A (FIGR)
- Raymond James Initiates SpyGlass Pharma(SGP.US) With Buy Rating, Announces Target Price $39
- Soracom: Commercial availability of the profile management platform "SORACOM Connectivity Hypervisor" has begun, enabling flexible operation of SGP.32‑compatible IoT SIMs.
- Soracom: Jointly developed an IoT SIM card compatible with the next-generation eSIM standard "SGP.32," with phased rollout beginning on July 7.
- Jefferies Maintains SpyGlass Pharma(SGP.US) With Buy Rating, Maintains Target Price $62
- Citi Initiates SpyGlass Pharma(SGP.US) With Buy Rating, Announces Target Price $42
- Analysts Offer Insights on NA Companies: SpyGlass Pharma (SGP) and Ottobock SE & Co. KGaA (OBCKF)
- Leerink Partners Initiates SpyGlass Pharma(SGP.US) With Buy Rating, Announces Target Price $42
- Jefferies Initiates SpyGlass Pharma(SGP.US) With Buy Rating, Announces Target Price $62
- Analysts Offer Insights on NA Companies: BitGo Holdings, Inc. Class A (BTGO) and SpyGlass Pharma (Nasdaq: SGP)
- H.C. Wainwright Initiates SpyGlass Pharma(SGP.US) With Buy Rating, Announces Target Price $37
- Citi Maintains SpyGlass Pharma(SGP.US) With Buy Rating, Maintains Target Price $42
- H.C. Wainwright Maintains SpyGlass Pharma(SGP.US) With Buy Rating, Maintains Target Price $37
- Analysts Have Conflicting Sentiments on These NA Companies: Fiserv (FISV), SpyGlass Pharma (Nasdaq: SGP) and Evommune, Inc. (EVMN)
暂无评论——快来第一个聊聊 SGP。
登录后参与讨论。